Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Loss of heparin-binding protein prevents necrotizing glomerulonephritis: first clues hint at plasminogen activator inhibitor-1.

┼×alaru DL, Mertens PR, Bartsch P.

Int Urol Nephrol. 2013 Oct;45(5):1483-7. doi: 10.1007/s11255-013-0415-1. Epub 2013 Mar 30. Review.

PMID:
23543126
2.

Deficiency of growth factor midkine exacerbates necrotizing glomerular injuries in progressive glomerulonephritis.

Kojima H, Kosugi T, Sato W, Sato Y, Maeda K, Kato N, Kato K, Inaba S, Ishimoto T, Tsuboi N, Matsuo S, Maruyama S, Yuzawa Y, Kadomatsu K.

Am J Pathol. 2013 Feb;182(2):410-9. doi: 10.1016/j.ajpath.2012.10.016. Epub 2012 Nov 27.

PMID:
23201132
3.

Plasminogen activator inhibitor-1 is a significant determinant of renal injury in experimental crescentic glomerulonephritis.

Kitching AR, Kong YZ, Huang XR, Davenport P, Edgtton KL, Carmeliet P, Holdsworth SR, Tipping PG.

J Am Soc Nephrol. 2003 Jun;14(6):1487-95.

4.

Apoptosis and glomerulonephritis.

Watson S, Cailhier JF, Hughes J, Savill J.

Curr Dir Autoimmun. 2006;9:188-204. Review.

PMID:
16394662
5.

Type 1 plasminogen activator inhibitor deficiency aggravates the course of experimental glomerulonephritis through overactivation of transforming growth factor beta.

Hertig A, Berrou J, Allory Y, Breton L, Commo F, Costa De Beauregard MA, Carmeliet P, Rondeau E.

FASEB J. 2003 Oct;17(13):1904-6. Epub 2003 Aug 1.

PMID:
12897066
6.
7.

Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis.

Kitching AR, Holdsworth SR, Ploplis VA, Plow EF, Collen D, Carmeliet P, Tipping PG.

J Exp Med. 1997 Mar 3;185(5):963-8.

8.

Resident kidney cells and their involvement in glomerulonephritis.

Timoshanko JR, Tipping PG.

Curr Drug Targets Inflamm Allergy. 2005 Jun;4(3):353-62. Review.

PMID:
16101545
9.

Complement synthesis in the injured kidney: does it have a role in immune complex glomerulonephritis?

Sacks SH, Zhou W, Sheerin NS.

J Am Soc Nephrol. 1996 Nov;7(11):2314-9. Review.

10.

[Role of hemostasis in the formation of crescents in extracapillary glomerulonephritis].

Rondeau E, Nguyen G, Adida C, Peraldi MN, Kanfer A, Sraer JD.

Nephrologie. 1992;13(6):259-62. Review. French.

PMID:
1299784
11.

Dysfunction of glomerular fibrinolysis in experimental antiglomerular basement membrane antibody glomerulonephritis.

Feng L, Tang WW, Loskutoff DJ, Wilson CB.

J Am Soc Nephrol. 1993 May;3(11):1753-64.

12.

Pathogenesis of glomerular damage in glomerulonephritis.

Couser WG.

Nephrol Dial Transplant. 1998;13 Suppl 1:10-5. Review.

PMID:
9507491
13.

Midkine, a heparin-binding cytokine with multiple roles in development, repair and diseases.

Muramatsu T.

Proc Jpn Acad Ser B Phys Biol Sci. 2010;86(4):410-25. Review.

14.

Tissue factor, plasminogen activator inhibitor-1, and thrombin receptor expression in human crescentic glomerulonephritis.

Grandaliano G, Gesualdo L, Ranieri E, Monno R, Schena FP.

Am J Kidney Dis. 2000 Apr;35(4):726-38.

PMID:
10739796
15.

Inhibiting inflammatory cytokines.

Kluth DC, Rees AJ.

Semin Nephrol. 1996 Nov;16(6):576-82. Review.

PMID:
9125802
16.

Does t-PA have a role in the treatment of crescentic glomerulonephritis?

McCluskey RT, Andres GA.

Lab Invest. 1990 Jan;62(1):1-4. Review. No abstract available.

PMID:
2104944
17.

Glomerulonephritis.

Remuzzi G, Zoja C, Bertani T.

Curr Opin Nephrol Hypertens. 1993 May;2(3):465-74. Review.

PMID:
7922207
18.

mRNA expression of urokinase and plasminogen activator inhibitor-1 in human crescentic glomerulonephritis.

Lee HS, Park SY, Moon KC, Hong HK, Song CY, Hong SY.

Histopathology. 2001 Aug;39(2):203-9.

PMID:
11493338
19.

Endogenous alpha2-antiplasmin does not enhance glomerular fibrin deposition or injury in glomerulonephritis.

Kitching AR, Turner AL, O'Sullivan KM, Dewerchin M, Lijnen HR.

J Thromb Haemost. 2003 Sep;1(9):1992-9.

20.

Supplemental Content

Support Center